Persistence in patients with acute schizophrenia treated with brexpiprazole in the Japanese clinical practice: a retrospective 6-month follow-up study

Persistence in patients with acute schizophrenia treated with brexpiprazole in the Japanese clinical practice: a retrospective 6-month follow-up study - Persistence in patients with acute schizophrenia treated with brexpiprazole in the Japanese clinical practice

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000051998

Enrollment

Registered

2023-08-31

Start date

2018-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophrenia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients at Karasuyama Hospital of Showa University. Patients who were diagnosed with schizophrenia according to the definitions outlined in the Diagnostic and Statistical Manual of Mental Disorders, fifth edition, and who were prescribed brexpiprazole at acute ward between August 2018 and August 2023.

Exclusion criteria

Exclusion criteria: Nothing

Design outcomes

Primary

Measure	Time frame
continuation rates and incidence of adverse effects	—

Countries

Japan

Contacts

Public ContactKazuki Shinmura

Showa University School of Medicine Department of Psychiatry

samurai.golf@med.showa-u.co.jp0333005231

Outcome results